| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PHAT | Common Stock | Sale | -$52K | -7.89K | -3.27% | $6.59 | 233K | 21 Jan 2025 | Direct | F1, F2, F3 |
| holding | PHAT | Common Stock | 3.58K | 21 Jan 2025 | By 401(k) | ||||||
| holding | PHAT | Common Stock | 786K | 21 Jan 2025 | By Trust |
| Id | Content |
|---|---|
| F1 | Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.5855 to $6.6650. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | Includes 1,973 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2025. |